Introduction
============

Angiotensin receptor blockers are now used widely for treatment of hypertension. They have actions that provide cardiovascular, stroke and renal protection [@R1], and their blood pressure (BP)-lowering efficacy appears to cover the full age spectrum of hypertension [@R5]. However, achieving recommended goal BPs during antihypertensive treatment requires combination therapy in a large proportion of patients [@R7]. Most of the available fixed-dose two-drug combinations include a thiazide or a thiazide-like diuretic as one of the agents, a strategy that has been recommended by guidelines in the USA [@R7].

More recently, however, fixed combinations based on either ACE inhibitors or angiotensin receptor blockers have included the dihydropyridine calcium channel blocker amlodipine [@R8]. These amlodipine combinations have been shown to have BP-lowering efficacies similar to diuretic combinations. Among the reasons for developing these newer combinations is that they avoid potential metabolic side effects of diuretic combinations and provide a therapeutic benefit for patients with such concomitant conditions as angina, for whom agents such as amlodipine would be indicated.

In addition, these newer combinations can offer some of the nonhemodynamic actions that might be associated with amlodipine [@R13]. In fact, in two major clinical outcomes trials where combinations of amlodipine with ACE inhibitors were compared with the combination of bendroflumethiazide with a β-blocker [@R15] or hydrochlorothiazide with an ACE inhibitor [@R16], the amlodipine combinations were associated with significantly lower cardiovascular event rates. The combination of blockers of the renin--angiotensin system with calcium channel blockers such as amlodipine has been recommended in the recent British guidelines on treating hypertension [@R17]. However, outcomes trials with combinations of amlodipine and angiotensin receptor blockers have not been conducted.

The angiotensin receptor blocker azilsartan medoxomil recently became available for treatment of hypertension and has been shown to be highly efficacious in reducing BP. This agent is a prodrug that is hydrolyzed to azilsartan, a powerful angiotensin receptor blocker with an elimination half-life of 12 h [@R18]. In a series of comparative studies, azilsartan medoxomil as a single agent was found to be more efficacious than other widely used angiotensin receptor blockers at their maximum approved doses [@R19]. These studies included comparisons with olmesartan, which itself appears to be one of the most efficacious agents in the class [@R21].

The present study was carried out as an initial exploration of the additional BP-lowering effects of azilsartan medoxomil combined with amlodipine. All patients in the trial received amlodipine 5 mg daily, the most widely used dose of this agent. Patients were randomized into three groups: those who received placebo plus amlodipine and those who received either 40 or 80 mg daily of azilsartan medoxomil plus amlodipine. We compared the antihypertensive effects of these therapeutic strategies using both ambulatory blood pressure monitoring (ABPM) and conventional clinic BP measurements, and also recorded adverse events.

Methods
=======

Study design
------------

This was a 6-week, randomized, double-blind, multicenter study designed to evaluate the antihypertensive efficacy and safety of the 40 and 80 mg doses of azilsartan medoxomil combined with 5 mg of the calcium channel blocker amlodipine, compared with placebo plus amlodipine 5 mg daily. The protocol conformed to the Declaration of Helsinki and regional regulatory guidelines and the study was approved by regional institutional review boards.

Selection of participants
-------------------------

Each patient signed a board-approved consent form before any study procedures were initiated. To qualify for randomization, each patient was required to be at least 18 years of age, to participate in a 3--4-week washout of previous antihypertensive therapy (which incorporated a 2-week single-blind, placebo run-in period), and to have a postwashout 24-h systolic BP ≥140 and ≤180 mmHg and a clinic systolic BP ≤160 and ≤190 mmHg. Participants could also have had diastolic hypertension if it was not excessive (i.e. \>119 mmHg). Exclusion criteria included secondary hypertension; severe renal impairment (estimated glomerular filtration rate \<30 ml/min/1.73 m^2^); history of a major cardiovascular event in the previous 6 months; type 1 or poorly controlled type 2 diabetes mellitus (hemoglobin A1c\>8%); a serum potassium concentration above the upper limit of normal; poor compliance with study medication during the placebo run-in period; and night-shift work. Pregnant or nursing women and women of childbearing potential not using approved means of contraception were also excluded, and use of medications known to affect BP was not allowed.

Treatments
----------

Participants were randomized to one of three treatment groups, including two combination groups and one monotherapy group. In the combination therapy arms, all participants received both active treatments as separate individual tablets (azilsartan medoxomil 40 mg+amlodipine 5 mg or azilsartan medoxomil 80 mg+amlodipine 5 mg), whereas the one-third of patients assigned to amlodipine 5 mg received matching placebo rather than active azilsartan medoxomil (i.e. placebo+amlodipine 5 mg).

Assessments and measurements
----------------------------

ABPM was performed before randomization and at week 6 using a Spacelabs 90207 monitor (Spacelabs Inc., Issaquah, Washington, USA). The monitor was fitted in the morning immediately after dosing and programmed to measure BP every 15 min between 6 a.m. and 10 p.m. and every 20 min between 10 p.m. and 6 a.m. A successful ABPM recording must have been at least 24 h in duration, captured at least 80% of the possible readings, had 2 nonconsecutive hours or less with less than one valid reading, and had no consecutive hours with less than one valid reading. If these criteria were not fulfilled, the procedure could be repeated within 5 days. Clinic BP was recorded at baseline and weeks 2, 4, and 6 using an automated device (Omron HEM 705-CP, Lake Forest, Illinois, USA). Clinic measurements were obtained in triplicate (same arm at least 2 min apart) ∼24 h after the previous dose of study medication (i.e. at trough) after the patient had been seated for 5 min and before other procedures were initiated.

Efficacy endpoints
------------------

Change from baseline to week 6 in 24-h systolic BP was the primary endpoint, and change in clinic systolic BP was the key secondary endpoint; changes in 24-h and clinic diastolic BP were also evaluated. Subgroup analyses were carried out by age, sex, race, BMI, and estimated glomerular filtration rate. The proportion of participants who achieved the BP target (\<140/90 mmHg) was also determined.

Statistical analysis
--------------------

The primary efficacy analysis was based on an analysis of covariance that included treatment as a factor and baseline 24-h systolic BP as a covariate. Missing data were handled using the last observation carried forward principle; type 1 error was controlled using 'closed' testing in which the pair-wise analyses between the individual treatment groups were carried out with no *P*-value adjustment only if the hypothesis 'all treatment groups are equal' was first rejected at the 0.05 level. Similar statistical methods were used to analyze the other secondary efficacy endpoints that were continuous variables. The proportion of participants who achieved clinic BP target was analyzed using a logistic model with treatment as a fixed effect and baseline clinic BP as a covariate. Assuming an SD of 13 mmHg and a 15% dropout rate, the planned sample size of this study (*N*=540, 180/group) provided at least 90% power to detect a difference of 5 mmHg between treatment groups for the primary endpoint.

Evaluation of safety
--------------------

Safety measures included adverse events, clinical laboratory results (including pregnancy testing), physical examination findings, and electrocardiographic data. All adverse events observed by the investigator or reported spontaneously by the patient were recorded and further characterized by the investigator as being nonserious or serious; whether or not the event led to discontinuation of treatment was also recorded. Safety laboratory parameters of interest that were measured at each visit included renal and hepatic function and serum potassium levels. Blood samples were analyzed by a central laboratory (ICON Laboratories, Farmingdale, New York, USA).

Results
=======

Study participants
------------------

Patient disposition and demographics are shown in [Fig. 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}, respectively. A total of 1469 patients were enrolled in the single-blind placebo run-in period at 73 sites in the USA, Peru, Mexico, and Chile, and 566 eligible patients were assigned randomly to double-blind treatment (≈190/group). A total of 532 (94%) completed the study as planned. Overall, the most common reason for premature discontinuation was voluntary withdrawal (*n*=13, 2.3%). Among randomized participants, the mean age was 58 years, with men and women equally represented; baseline 24-h BP (153--154/93 mmHg) and clinic BP (165--166/94--95 mmHg) were similar across groups. There were no major differences with respect to other demographic characteristics ([Table 1](#T1){ref-type="table"}).

![Patient disposition. Data are *n* (%). AML, amlodipine; AZL-M, azilsartan medoxomil; BP, blood pressure. The category 'other' includes discontinuations that were because of reasons other than an adverse event, lack of efficacy, voluntary withdrawal, loss to follow-up, or protocol deviation. ^a^Includes one patient who was not randomized but received active study drug.](mbp-19-90-g001){#F1}

###### 

Demographic characteristics of randomized patients

![](mbp-19-90-g002)

Changes in systolic blood pressure
----------------------------------

BP changes after 6 weeks of randomized treatment are shown in [Fig. 2](#F2){ref-type="fig"}. Decreases were observed in all treatment groups for the primary endpoint of 24-h systolic BP, with reductions of ∼25 mmHg in both the azilsartan medoxomil 40 mg+amlodipine 5 mg and the azilsartan medoxomil 80 mg+amlodipine 5 mg groups, which were statistically significantly greater than the 14 mmHg reduction observed with placebo+amlodipine 5 mg (*P*≤0.001 for both comparisons). Reductions in other systolic ABPM parameters were consistent with the 24-h results; daytime and night-time reductions in the azilsartan medoxomil+amlodipine groups were ∼25/16 and 23/14 mmHg, respectively, whereas in the placebo+amlodipine 5 mg group, these parameters were reduced by 14/8 and 13/8 mmHg (*P*\<0.001 for each comparison). The mean systolic BP values observed at each hour of the week 6 ambulatory recording are shown in [Fig. 3](#F3){ref-type="fig"}.

![Change from baseline in 24-h and clinic BP at week 6. AML, amlodipine; AZL-M, azilsartan medoxomil; BP, blood pressure. Data are least-squares mean (±SE). \**P*≤0.001 vs. placebo+AML 5 mg.](mbp-19-90-g003){#F2}

![Ambulatory blood pressure at each hour after dosing at week 6. AML, amlodipine; AZL-M, azilsartan medoxomil.](mbp-19-90-g004){#F3}

For clinic systolic BP, significantly greater reductions of 26--27 mmHg were observed in the azilsartan medoxomil+amlodipine groups compared with 16 mmHg in the placebo+amlodipine group at week 6 (*P*\<0.001 for each comparison; [Fig. 2](#F2){ref-type="fig"}). Statistically significant reductions were also observed in favor of both azilsartan medoxomil+amlodipine groups at the other study visits, with near maximal effects achieved by the week 2 visit (−23 mmHg in the azilsartan medoxomil+amlodipine groups and −14 mmHg in the placebo+amlodipine group).

Subgroup analyses of the primary endpoint showed statistically significantly greater reductions in 24-h systolic BP in both azilsartan medoxomil+amlodipine groups relative to placebo+amlodipine irrespective of age (\<65 and ≥65 years), sex, race (white, black, other), or BMI (\<30 and ≥30 kg/m^2^) (*P*\<0.05 for each comparison).

Additional endpoints
--------------------

Changes in diastolic pressures, as measured by both ambulatory and clinic measurements, were consistently statistically significantly greater in both azilsartan medoxomil+amlodipine groups versus placebo+amlodipine. Reductions in 24-h diastolic BP were ∼15 mmHg with azilsartan medoxomil+amlodipine combination therapy and 8 mmHg with placebo+amlodipine, and reductions in clinic diastolic BP were 12--13 mmHg with combination therapy compared with 7 mmHg for placebo+amlodipine (*P*\<0.001 for each comparison; [Fig. 2](#F2){ref-type="fig"}). The proportions of patients whose individual reductions in clinic systolic and/or diastolic BP achieved the target were also significantly greater in both azilsartan medoxomil+amlodipine treatment groups compared with placebo+amlodipine ([Fig. 4](#F4){ref-type="fig"}).

![Percent of participants achieving the blood pressure target at week 6. AML, amlodipine; AZL-M, azilsartan medoxomil; DBP, diastolic blood pressure; SBP, systolic blood pressure. \**P*\<0.001 vs. placebo+amlodipine.](mbp-19-90-g005){#F4}

Safety and tolerability
-----------------------

The safety findings are summarized in [Table 2](#T2){ref-type="table"}. At least one adverse event was reported by 253 (45%) participants across all treatment groups. The rate of adverse events was similar in the placebo+amlodipine 5 mg (47%) and azilsartan medoxomil 40 mg+amlodipine 5 mg (48%) groups, with a slightly lower rate in the azilsartan medoxomil 80 mg+amlodipine 5 mg group (40%). Edema was less common in both azilsartan medoxomil+amlodipine groups (3%) compared with placebo+amlodipine (7.6%). Diarrhea was reported most frequently in the azilsartan medoxomil 40 mg+amlodipine 5 mg group, but no cases were observed in the azilsartan medoxomil 80 mg+amlodipine 5 mg group. There were no deaths in the study. Four participants experienced serious adverse events ([Table 2](#T2){ref-type="table"}), with one event of syncope that was considered related to treatment (azilsartan medoxomil 40 mg+amlodipine 5 mg) and led to withdrawal of the patient.

###### 

Safety findings

![](mbp-19-90-g006)

In clinical laboratory tests, there were small mean increases in creatinine (0.4--2.2 μmol/l), potassium (0.11--0.13 mmol/l), and uric acid (2.7--8.5 μmol/l) in the azilsartan medoxomil+amlodipine groups compared with slight decreases (−0.3,−1.0, −10.7 μmol/l, respectively) in the placebo+amlodipine group. However, no individual participant had a persistent serum creatinine elevation of at least 50% above baseline and above the upper limit of normal; hyperkalemia (serum potassium \>6 mmol/l) was rare (one participant in each azilsartan medoxomil+amlodipine group); and there were few cases of gout (one patient with azilsartan medoxomil+amlodipine and one with placebo+amlodipine). There were no major differences for other clinical safety laboratory parameters (including hepatic transaminases, hematocrit, and hemoglobin) or ECGs.

Discussion
==========

The combinations of azilsartan medoxomil (40 or 80 mg daily) with amlodipine 5 mg produced similar 24-hour BP reductions of ∼25/15 mmHg in this study of patients with stage 2 hypertension. As there is generally little or no placebo effect with the use of ABPM, this result shows the powerful efficacy of these combinations. Of note, the BP reductions with the combination treatments averaged 10/7 mmHg more than with amlodipine as a single agent. These comparative effects were similar in the daytime and night-time periods and were sustained across the full 24 h. There was no difference between the two azilsartan medoxomil doses in their effects on BP in this study.

The clinic BP measurements showed similar results for the combinations and single agent groups. With less than 140/90 mmHg as the criterion for BP control, 49 and 46% of patients receiving the 40 and 80 mg azilsartan medoxomil+amlodipine combinations achieved this target, compared with 25% for the placebo+amlodipine group. This degree of target achievement is a strong finding for this combination in the setting of stage 2 hypertension, particularly bearing in mind that the 5 mg dose of the amlodipine component used in this study is not the maximum dose of that drug.

These results are not surprising. Previous studies of combinations of amlodipine with angiotensin receptor blockers have reported strong antihypertensive effects when the 5 mg dose of amlodipine has been used [@R9]. Even though azilsartan medoxomil as monotherapy has been shown to be more effective than the angiotensin receptor blockers used in those previous combination studies [@R19], we cannot make any judgments on the relative efficacies of amlodipine/angiotensin receptor blocker combinations without carrying out direct head-to-head studies.

Azilsartan medoxomil has also been evaluated in combination with the thiazide-like diuretic chlorthalidone [@R23]. This diuretic is a powerful antihypertensive agent that also has shown outcomes benefits in clinical trials [@R25]. Its usual dose in contemporary medical practice has been 12.5 or 25 mg. When the lower dose of chlorthalidone was used in the combination studies with azilsartan medoxomil, BP reductions were similar to those observed in the present study using the 5 mg dose of amlodipine in combination with azilsartan medoxomil [@R27]. As shown previously, the combination of the angiotensin receptor blockers with either amlodipine or a thiazide diuretic will likely provide effective therapy for patients with more difficult-to-control hypertension [@R28].

Although calcium channel blockers such as amlodipine are effective and generally well tolerated, they are more likely than other commonly used antihypertensive agents to cause peripheral edema. This effect may be because of these drugs causing a greater degree of arterial than venous dilation, an effect that can cause peripheral pooling. As blockers of the renin--angiotensin system work on both venous and arterial beds, their combination with such drugs as amlodipine can attenuate this unwanted effect.

The combination of an ACE inhibitor [@R8] or an angiotensin receptor blocker [@R9] with amlodipine has been associated with lower rates of peripheral edema than amlodipine alone, and a similar effect was observed in the present study when azilsartan medoxomil was combined with amlodipine, even though the treatment period was relatively short and the overall number of edema reports was low. The incidence of other adverse events was low and did not appear to differ between the combination therapies and the single agent. This tolerability has been shown previously in studies of angiotensin receptor blocker/amlodipine combinations [@R9] and has also been observed during long-term treatment with ACE inhibitor/amlodipine combinations [@R16].

This study was an initial exploratory trial to determine the potential value of azilsartan medoxomil/amlodipine combinations in treating hypertension. However, this experience was limited to only the 5 mg dose of amlodipine. Previous work with combination therapies has shown that 10 mg of amlodipine is meaningfully more powerful in reducing BP than 5 mg [@R30], and so it would be valuable to learn from a well-conducted clinical trial whether an even greater proportion of patients with stage 2 hypertension could have their BPs controlled with this higher dose. It has also been reported that the higher amlodipine dose is more likely to cause peripheral edema; thus, it would be important to confirm that azilsartan medoxomil could reduce the incidence or the severity of this effect.

Another limitation of this study is that we did not have a placebo-only group, even though the key observations of the BP effects of azilsartan medoxomil when added to amlodipine were compared with a control group in which placebo was added to amlodipine. In any case, it is accepted that ABPM usually prevents a placebo effect on BP; it is still useful to more accurately define the true effect of the active treatment. In addition, placebo control can be important in understanding the incidence of adverse events.

Conclusion
----------

This study has shown that the combination of azilsartan medoxomil with amlodipine exerts a robust additional antihypertensive effect compared with placebo plus amlodipine. These data provide a strong justification for a multifactorial trial to help define which combinations of azilsartan medoxomil and amlodipine will provide optimal safety and efficacy in the treatment of hypertension.
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